DGAP-News: Defence Therapeutics Inc.: Defence Therapeutics development program to engineer a new HPV vaccine initiated

DGAP-News: Defence Therapeutics Inc. / Key word(s): Miscellaneous
DEFENCE THERAPEUTICS DEVELOPMENT PROGRAM TO ENGINEER A NEW HPV VACCINE INITIATED

07.09.2021 / 08:30
The issuer is solely responsible for the content of this announcement.

---

CSE: DTC FSE: DTC OTC: DTCFF PRESS RELEASE

DEFENCE THERAPEUTICS DEVELOPMENT PROGRAM TO ENGINEER A NEW HPV VACCINE INITIATED

Vancouver, BC, Canada, September 7^th, 2021 - Defence Therapeutics Inc. ("Defence" or the "Company"), a biotechnology company working on ADC therapeutics for cancer targeting with its Accum^TM technology and cancer vaccine therapeutics and infectious disease vaccines, is pleased to announce the establishment of a high priority program to develop a novel HPV-targeting vaccine for cervical cancer with it's Accum^TM technology.

Currently there are more than 40 types of HPV strains capable of affecting the genital areas, mouth and throat of both males and females. This makes HPV one of the most common sexually transmitted disease worldwide. Just in the USA, 79 million Americans are currently infected with the virus, and 14 million will roughly become newly infected each year according to the center for disease control. Although most people with HPV never develop symptoms or health problems, HPV infections will persist resulting in life-threatening health issues such as genital warts, cervical, oropharyngeal, anal, vulvar, vaginal and penile cancer.

"Even though current HPV vaccines produce high antibody titers, they do not protect against all types of HPV. Additional efforts are therefore required to develop more efficacious vaccines that can not only trigger a good antibody and cellular response but provide in addition an excellent memory response to ensure good long-term protection over at least 20 years post-vaccination" says Mr. Sebastien Plouffe, the CEO of Defence Therapeutics.

"Defence's Accum^TM technology is highly versatile and can be applied to any protein for potential enhancement. Accum^TM has shown from our past vaccine studies that the use of this platform can design novel protein-based vaccines that will amplify the immune response and can generate amplification in current vaccines," he added.

The global Human Papillomavirus (HPV) Vaccine market size was valued at USD 3.8 billion in 2019 and is projected to reach USD 12.69 billion by 2027, exhibiting a CAGR of 16.3% during the forecast period according to Fortune Business Insights.

About Defence:
Defence Therapeutics is a publicly-traded biotechnology company working on engineering the next generation vaccines and ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUM^TM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. As a result, increased efficacy and potency can be reached against catastrophic illness such as cancer and infectious diseases.

For further information:
Sebastien Plouffe, President, CEO and Director
P: [phone]
[e-mail]
www.defencetherapeutics.com

Cautionary Statement Regarding "Forward-Looking" Information

This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.

---

07.09.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

---

Language:	English
Company:	Defence Therapeutics Inc.
	1680 - 200 Burrard St
	V6C3L6 Vancouver
	Canada
E-mail:	[e-mail]
Internet:	https://defencetherapeutics.com
ISIN:	CA24463V1013
WKN:	A3CN14
Listed:	Regulated Unofficial Market in Frankfurt, Stuttgart; Toronto
EQS News ID:	1231609

End of News	DGAP News Service

---

1231609 07.09.2021